Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cara Therapeutics (CARA)
Cara Therapeutics (CARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,420
  • Shares Outstanding, K 54,481
  • Annual Sales, $ 41,870 K
  • Annual Income, $ -85,470 K
  • 60-Month Beta 0.59
  • Price/Sales 2.31
  • Price/Cash Flow N/A
  • Price/Book 0.43
Trade CARA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.15
  • Most Recent Earnings $-0.52 on 11/13/23
  • Latest Earnings Date 03/04/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 357.79% ( -321.44%)
  • Historical Volatility 91.91%
  • IV Percentile 83%
  • IV Rank 31.08%
  • IV High 1,103.16% on 01/08/24
  • IV Low 21.66% on 08/16/23
  • Put/Call Vol Ratio 0.06
  • Today's Volume 183
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 2,418
  • Open Int (30-Day) 3,901

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.58
  • Number of Estimates 4
  • High Estimate -0.55
  • Low Estimate -0.61
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -3.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5000 +81.42%
on 01/25/24
1.1300 -19.73%
on 02/23/24
+0.3371 (+59.14%)
since 01/23/24
3-Month
0.5000 +81.42%
on 01/25/24
1.3100 -30.76%
on 12/15/23
-0.0552 (-5.74%)
since 11/22/23
52-Week
0.5000 +81.42%
on 01/25/24
10.3900 -91.27%
on 03/03/23
-9.4329 (-91.23%)
since 02/23/23

Most Recent Stories

More News
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 1.0000 (-5.66%)
CARA : 0.9071 (+13.56%)
CRBP : 25.75 (+1.18%)
HRMY : 32.50 (+3.34%)
JAZZ : 132.28 (+2.98%)
Cara: Q3 Earnings Snapshot

Cara: Q3 Earnings Snapshot

CARA : 0.9071 (+13.56%)
Cara: Q2 Earnings Snapshot

Cara: Q2 Earnings Snapshot

CARA : 0.9071 (+13.56%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/CNW/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for...

CARA : 0.9071 (+13.56%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute...

CARA : 0.9071 (+13.56%)
Cara: Q1 Earnings Snapshot

Cara: Q1 Earnings Snapshot

CARA : 0.9071 (+13.56%)
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DARE : 0.5352 (+21.64%)
CARA : 0.9071 (+13.56%)
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SCPH : 5.66 (+0.35%)
CARA : 0.9071 (+13.56%)
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -0.66% and 37.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RGNX : 17.41 (-4.18%)
CARA : 0.9071 (+13.56%)
Stocks Slide After the Fed Chairman Powell Warns Rates Will Likely Be Higher

Morning Markets The S&P 500 Index ( $SPX ) ( SPY ) today is down -0.41%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) is down -0.46%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is down -0.25%. Stock...

ESH24 : 5,101.50s (+0.07%)
NQH24 : 17,991.00s (-0.31%)
META : 484.03 (-0.43%)
DKS : 172.67 (+2.24%)
UAL : 45.51 (+0.55%)
TCOM : 47.34 (+5.98%)
SQSP : 32.22 (+0.12%)
DISH : 5.77 (+1.94%)
NTNX : 58.76 (+0.72%)
RIVN : 10.07 (-12.05%)
KEY : 14.26 (-0.63%)
ZYXI : 12.91 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

See More

Key Turning Points

3rd Resistance Point 1.3947
2nd Resistance Point 1.2624
1st Resistance Point 1.0847
Last Price 0.9071
1st Support Level 0.7747
2nd Support Level 0.6424
3rd Support Level 0.4647

See More

52-Week High 10.3900
Fibonacci 61.8% 6.6120
Fibonacci 50% 5.4450
Fibonacci 38.2% 4.2780
Last Price 0.9071
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar